Orexin B Reduces Cerebral Aneurysms Through Inhibition of SP ‐1
CNS Neuroscience & Therapeutics · 2026-06 · 32 (6)
DOI: 10.1002/cns.70958 ↗Kurz gefasst
Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, online erschienen am 08.06.2026. Verfasst von Lei Chen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, Guangdong, China. Hauptthemen laut MEDLINE: Intracranial Aneurysm, Orexins, Sp1 Transcription Factor. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dongguan Science and Technology of Social Development Program, Talent Development Foundation of The First Dongguan Affiliated Hospital of Guangdong Medical University, Guangdong Medical Research Fund project.
Abstract (Originalsprache)
Background
Cerebral aneurysms (CAs) are pathological dilations of intracranial arteries with high rupture risk, yet the molecular mechanisms driving their formation remain incompletely understood. The Orexin B/OX2R system, known for regulating arousal and metabolism, has recently been implicated in vascular pathology, but its role in CAs has not been explored.
Methods
Serum Orexin A and B levels were measured in 38 CA patients and 43 healthy controls. A murine CA model (elastase‐induced) was established using wild‐type (WT) and OX2R knockout ( OX2R −/− ) mice, with or without Orexin B treatment (30 μg/kg/day for 7 weeks). Aneurysm size, inflammatory mediators (IL‐6, MMP‐9, MCP‐1, E‐selectin), macrophage infiltration (CD68), and SP‐1 expression were assessed. In vitro studies using human brain microvascular endothelial cells (HBMVECs) examined Ang II‐induced OX2R suppression, monocyte adhesion, and SP‐1‐mediated signaling following Orexin B treatment and SP‐1 overexpression.
Results
CA patients and mice exhibited significantly reduced serum Orexin B levels (CA patients: 3.21 ± 0.52 vs. controls: 8.56 ± 1.23 pg/mL, p < 0.01), with no change in Orexin A. OX2R expression was downregulated in the circle of Willis of CA mice. Orexin B administration attenuated aneurysm formation in WT mice (size reduction from 3.72 ± 0.469 mm to 1.93 ± 0.252 mm, p < 0.01) but not in OX2R −/− mice. Orexin B suppressed IL‐6, MMP‐9, MCP‐1, and E‐selectin expression, reduced CD68+ macrophage infiltration, and decreased SP‐1 levels in WT but not OX2R −/− mice. In HBMVECs, Ang II dose‐dependently reduced OX2R expression. Orexin B inhibited Ang II‐induced monocyte adhesion and SP‐1‐mediated pro‐inflammatory signaling, effects abolished by OX2R siRNA or SP‐1 overexpression.
Conclusions
The Orexin B/OX2R axis is dysregulated in CAs, and Orexin B protects against CA formation through OX2R‐dependent anti‐inflammatory mechanisms involving SP‐1 suppression. These findings identify the Orexin B/OX2R/SP‐1 pathway as a potential therapeutic target for cerebral aneurysms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, Guangdong, China.
- Department of Neurology, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, Guangdong, China.
ORCID-Profile: Huimin Yu
Förderung
- Dongguan Science and Technology of Social Development Program
- Talent Development Foundation of The First Dongguan Affiliated Hospital of Guangdong Medical University
- Guangdong Medical Research Fund project
Zitieren
APA
Chen, L., Xu, J., Ye, F., Luo, J., & Yu, H. (2026). Orexin B Reduces Cerebral Aneurysms Through Inhibition of SP ‐1. CNS Neuroscience & Therapeutics, 32(6). https://doi.org/10.1002/cns.70958
Vancouver
Chen L, Xu J, Ye F, Luo J, Yu H. Orexin B Reduces Cerebral Aneurysms Through Inhibition of SP ‐1. CNS Neuroscience & Therapeutics. 2026;32(6). doi:10.1002/cns.70958
BibTeX
@article{Chen2026,
author = {Chen, Lei and Xu, Jinlong and Ye, Fengyun and Luo, Jiajia and Yu, Huimin},
title = {Orexin B Reduces Cerebral Aneurysms Through Inhibition of SP ‐1},
journal = {CNS Neuroscience & Therapeutics},
year = {2026},
volume = {32},
number = {6},
doi = {10.1002/cns.70958}
}
EUVIMED